Tencent begins clinical trial using AI to diagnose Parkinson’s

Amy Baxter | | Health Exec | Precision Medicine

Technology giant Tencent has begun a clinical trial in London of its AI program to diagnose Parkinson’s disease, Financial Times reported.

The company partnered with Medopad, a healthcare technology startup based in London, last year to create a new lab for AI, where they plan to target Parkinson’s, multiple sclerosis and psoriasis. Tencent and Medopad are also working with the Parkinson’s Center of Excellence at King’s College Hospital in London.

The clinical trial will take place at a private mental health clinic in London, Dementech Neurosciences, and will involve roughly 40 patients over the next few months.

Tencent’s partnership with Medopad, which does not yet include a financial investment in the company itself, is viewed as a refocus for the company to experiment in the healthcare space, Financial Times reported.

According to the publication, the UK is a burgeoning place for AI in healthcare startups and more established technology bigwigs, with Google's DeepMind partnering with several British hospitals to remotely monitor patients using technology.

See the full story below:

Tencent trials AI diagnosis program for Parkinson’s in London

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup